Skip to main content
Top
Published in: Critical Care 2/2010

Open Access 01-04-2010 | Research

Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study

Authors: Thomas Benfield, Karen Ejrnæs, Klaus Juul, Christian Østergaard, Jannik Helweg-Larsen, Nina Weis, Lea Munthe-Fog, Gitte Kronborg, Marianne Ring Andersen, Anne Tybjærg-Hansen, Børge G Nordestgaard, Peter Garred

Published in: Critical Care | Issue 2/2010

Login to get access

Abstract

Introduction

Disturbance of the pro-coagulatant and anti-coagulant balance is associated with a poor outcome from critical illness. The objective of this study is to determine whether the Factor V Leiden (FVL) mutation is associated with susceptibility to or death from critical illness.

Methods

A genetic association study involving four case cohorts comprising two Gram negative sepsis, one invasive pneumococcal disease and one intensive care unit cohort with a total of 1,249 patients. Controls were derived from a population-based cohort study (N = 8,147). DNA from patients and controls was genotyped for the FVL mutation.

Results

When all patients were investigated together no significant difference in the frequency of FVL mutation was observed compared with controls (odds ratio (OR), 1.03; 95% confidence interval (CI), 0.83 to 1.29). However, when stratified among patients admitted to intensive care (N = 237), susceptibility and the likelihood of long-term death was influenced by the FVL mutation. In adjusted logistic regression analysis, FVL carriers had an increased risk of ICU admission compared to non-carriers (OR 1.62; 95% CI, 1.08 to 2.42). In adjusted Cox regression analysis, FVL carriers were at increased risk of long-term death compared to non-carriers (relative risk 1.78; 95% CI, 1.13 to 2.81). FVL carrier status did not predict either susceptibility to or outcome from Gram negative, Escherichia coli or Streptococcus pneumoniae sepsis.

Conclusions

Overall, the FVL mutation did not appear to increase the risk of admission due to severe invasive infections. Nevertheless, in the subgroup of patients admitted to intensive care an increased risk and a poorer long-term outcome for individuals with critical illness were observed for FVL mutation carriers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997, 349: 1269-1276. 10.1016/S0140-6736(96)07493-4.CrossRefPubMed Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997, 349: 1269-1276. 10.1016/S0140-6736(96)07493-4.CrossRefPubMed
2.
go back to reference Beaglehole R, Irwin A, Prentice T: The World Health Report: 2003: Shaping the Future. 2003, World Health Organization Beaglehole R, Irwin A, Prentice T: The World Health Report: 2003: Shaping the Future. 2003, World Health Organization
3.
go back to reference Kochanek KD, Murphy SL, Anderson RN, Scott C: Deaths: final data for 2002. National Vital Statistics Report. 2004, Hyattsville, Md., National Center for Health Statistics, 53 (8): Kochanek KD, Murphy SL, Anderson RN, Scott C: Deaths: final data for 2002. National Vital Statistics Report. 2004, Hyattsville, Md., National Center for Health Statistics, 53 (8):
4.
go back to reference Bochud PY, Bochud M, Telenti A, Calandra T: Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis. 2007, 7: 531-542. 10.1016/S1473-3099(07)70185-8.CrossRefPubMed Bochud PY, Bochud M, Telenti A, Calandra T: Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis. 2007, 7: 531-542. 10.1016/S1473-3099(07)70185-8.CrossRefPubMed
5.
go back to reference Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Velden van der PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994, 369: 64-67. 10.1038/369064a0.CrossRefPubMed Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Velden van der PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994, 369: 64-67. 10.1038/369064a0.CrossRefPubMed
6.
go back to reference Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG: Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med. 2004, 140: 330-337.CrossRefPubMed Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG: Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med. 2004, 140: 330-337.CrossRefPubMed
7.
go back to reference Mann KG, Kalafatis M: Factor V: a combination of Dr Jekyll and Mr Hyde. Blood. 2003, 101: 20-30. 10.1182/blood-2002-01-0290.CrossRefPubMed Mann KG, Kalafatis M: Factor V: a combination of Dr Jekyll and Mr Hyde. Blood. 2003, 101: 20-30. 10.1182/blood-2002-01-0290.CrossRefPubMed
8.
go back to reference Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut J-F: Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003, 102: 3085-3092. 10.1182/blood-2003-06-1789.CrossRefPubMed Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut J-F: Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003, 102: 3085-3092. 10.1182/blood-2003-06-1789.CrossRefPubMed
9.
go back to reference Adamzik M, Frey UH, Riemann K, Sixt S, Lehmann N, Siffert W, Peters J: Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome. Crit Care Med. 2008, 36: 1776-1779. 10.1097/CCM.0b013e318174373d.CrossRefPubMed Adamzik M, Frey UH, Riemann K, Sixt S, Lehmann N, Siffert W, Peters J: Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome. Crit Care Med. 2008, 36: 1776-1779. 10.1097/CCM.0b013e318174373d.CrossRefPubMed
10.
go back to reference Yan SB, Nelson DR: Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med. 2004, 32: S239-S246. 10.1097/01.CCM.0000126122.34119.D1.CrossRefPubMed Yan SB, Nelson DR: Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med. 2004, 32: S239-S246. 10.1097/01.CCM.0000126122.34119.D1.CrossRefPubMed
11.
go back to reference Bruggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA: Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med. 2006, 34: 2201-2206. 10.1097/01.CCM.0000228918.30931.E8.CrossRefPubMed Bruggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA: Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med. 2006, 34: 2201-2206. 10.1097/01.CCM.0000228918.30931.E8.CrossRefPubMed
12.
go back to reference Sun H, Wang X, Degen JL, Ginsburg D: Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood. 2009, 113: 1358-1364. 10.1182/blood-2008-07-170506.PubMedCentralCrossRefPubMed Sun H, Wang X, Degen JL, Ginsburg D: Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood. 2009, 113: 1358-1364. 10.1182/blood-2008-07-170506.PubMedCentralCrossRefPubMed
13.
go back to reference Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M: Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J. 1999, 18: 893-896. 10.1097/00006454-199910000-00011.CrossRefPubMed Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M: Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J. 1999, 18: 893-896. 10.1097/00006454-199910000-00011.CrossRefPubMed
14.
go back to reference Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A: Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis. 2005, 192: 1851-1857. 10.1086/497167.CrossRefPubMed Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A: Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis. 2005, 192: 1851-1857. 10.1086/497167.CrossRefPubMed
15.
go back to reference Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG: Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med. 1998, 338: 1577-1584. 10.1056/NEJM199805283382203.CrossRefPubMed Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG: Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med. 1998, 338: 1577-1584. 10.1056/NEJM199805283382203.CrossRefPubMed
16.
go back to reference Jessen KM, Lindboe SB, Petersen AL, Eugen-Olsen J, Benfield T: Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC Infect Dis. 2007, 7: 108-10.1186/1471-2334-7-108.PubMedCentralCrossRefPubMed Jessen KM, Lindboe SB, Petersen AL, Eugen-Olsen J, Benfield T: Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC Infect Dis. 2007, 7: 108-10.1186/1471-2334-7-108.PubMedCentralCrossRefPubMed
17.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992, 101: 1644-1655. 10.1378/chest.101.6.1644.CrossRefPubMed Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992, 101: 1644-1655. 10.1378/chest.101.6.1644.CrossRefPubMed
18.
go back to reference Garred P, Strom J, Quist L, Taaning E, Madsen HO: Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis. 2003, 188: 1394-1403. 10.1086/379044.CrossRefPubMed Garred P, Strom J, Quist L, Taaning E, Madsen HO: Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis. 2003, 188: 1394-1403. 10.1086/379044.CrossRefPubMed
19.
go back to reference Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Hjuler T, Kaltoft M, Krogfelt KA, Lambertsen L, Konradsen HB: Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine. 2008, 26: 3765-3771. 10.1016/j.vaccine.2008.04.040.CrossRefPubMed Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Hjuler T, Kaltoft M, Krogfelt KA, Lambertsen L, Konradsen HB: Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine. 2008, 26: 3765-3771. 10.1016/j.vaccine.2008.04.040.CrossRefPubMed
20.
go back to reference Kronborg G, Weis N, Madsen HO, Pedersen SS, Wejse C, Nielsen H, Skinhoj P, Garred P: Variant mannose-binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in randomly included patients. J Infect Dis. 2002, 185: 1517-1520. 10.1086/340216.CrossRefPubMed Kronborg G, Weis N, Madsen HO, Pedersen SS, Wejse C, Nielsen H, Skinhoj P, Garred P: Variant mannose-binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in randomly included patients. J Infect Dis. 2002, 185: 1517-1520. 10.1086/340216.CrossRefPubMed
21.
go back to reference Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG: Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002, 100: 3-10. 10.1182/blood-2002-01-0111.CrossRefPubMed Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG: Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002, 100: 3-10. 10.1182/blood-2002-01-0111.CrossRefPubMed
22.
go back to reference Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A: The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997, 336: 399-403. 10.1056/NEJM199702063360602.CrossRefPubMed Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A: The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997, 336: 399-403. 10.1056/NEJM199702063360602.CrossRefPubMed
23.
go back to reference Bergh van den FA, van Oeveren-Dybicz AM, Bon MA: Rapid single-tube genotyping of the factor V Leiden and prothrombin mutations by real-time PCR using dual-color detection. Clin Chem. 2000, 46: 1191-1195.PubMed Bergh van den FA, van Oeveren-Dybicz AM, Bon MA: Rapid single-tube genotyping of the factor V Leiden and prothrombin mutations by real-time PCR using dual-color detection. Clin Chem. 2000, 46: 1191-1195.PubMed
24.
go back to reference Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainault J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely W, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344: 699-709. 10.1056/NEJM200103083441001.CrossRefPubMed Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainault J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely W, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344: 699-709. 10.1056/NEJM200103083441001.CrossRefPubMed
25.
go back to reference Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004, 351: 2611-2618. 10.1056/NEJMoa041747.CrossRefPubMed Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004, 351: 2611-2618. 10.1056/NEJMoa041747.CrossRefPubMed
26.
go back to reference Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P: Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006, 367: 1075-1079. 10.1016/S0140-6736(06)68474-2.CrossRefPubMed Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P: Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006, 367: 1075-1079. 10.1016/S0140-6736(06)68474-2.CrossRefPubMed
Metadata
Title
Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study
Authors
Thomas Benfield
Karen Ejrnæs
Klaus Juul
Christian Østergaard
Jannik Helweg-Larsen
Nina Weis
Lea Munthe-Fog
Gitte Kronborg
Marianne Ring Andersen
Anne Tybjærg-Hansen
Børge G Nordestgaard
Peter Garred
Publication date
01-04-2010
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2010
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc8899

Other articles of this Issue 2/2010

Critical Care 2/2010 Go to the issue